Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

BEIGENE, LTD.

(BGNE)
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
Beroep
Logo BeiGene, Ltd.
BeiGene, Ltd. houdt zich voornamelijk bezig met biofarmaceutische zaken. De Vennootschap houdt zich voornamelijk bezig met onderzoek en ontwikkeling, productie en verkoop van innovatieve moleculair gerichte en immuno-oncologische geneesmiddelen voor de behandeling van kanker. De belangrijkste producten van de Vennootschap zijn Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) en Pamiparib (BGB-290).

Aantal werknemers : 5 300 mensen.
Verkoop per activiteit
20192020Delta
Pharmaceutical Products428.21100%308.87100% -27.87%
USD in miljoenen
Verkoop per regio
20192020Delta
China221.5651.7%290.6594.1% +31.18%
United States134.6931.5%18.235.9% -86.47%
Other71.9716.8%---
USD in miljoenen
Managers
Naam Titel Leeftijd Van
John Oyler Chairman & Chief Executive Officer 52 2016
Xiao Bin Wu President & Chief Operating Officer 58 2021
Julia Wang Chief Financial & Accounting Officer 49 2021
Jane Huang Chief Medical Officer-Hematology 47 2016
Yong Ben Chief Medical Officer-Immuno & Oncology Department - 2019
Lai Wang Global Head-Research & Development 43 2021
Christiane Langer Senior Vice President-Global Medical Affairs - 2021
Michael J. Goller Independent Non-Executive Director 45 2015
Donald W. Glazer Independent Non-Executive Director 75 2013
Ranjeev Krishana Independent Non-Executive Director 46 2014
Bestuurders
Naam Titel Leeftijd Van
John Oyler Chairman & Chief Executive Officer 52 2016
Michael J. Goller Independent Non-Executive Director 45 2015
Donald W. Glazer Independent Non-Executive Director 75 2013
Ranjeev Krishana Independent Non-Executive Director 46 2014
Qing Qing Yi Independent Non-Executive Director 48 2014
Xiao Dong Wang Non-Executive Director 57 2016
Thomas R. Malley Independent Non-Executive Director 51 2016
Yong Zheng Chen Independent Non-Executive Director 63 2016
Jing Shyh Su Independent Non-Executive Director 67 2018
Anthony C. Hooper Non-Executive Director 65 2020
Aandelen
Stemming AantalPercentage vrij verhandelbaarBedrijfseigen aandelenDrijvend Totaal
Aandeel A 0.07692 1 204 567 023 821 244 594 68.2% 0 0.0% 68.2%
Aandeelhouders
NaamAandelen%
Baker Bros. Advisors LP 11 668 897 12,6%
Capital Research & Management Co. (International Investors) 5 939 650 6,41%
HHLR Advisors Ltd. 5 472 259 5,90%
Baillie Gifford & Co. 4 272 178 4,61%
Fidelity Management & Research Co. LLC 4 250 793 4,59%
PRIMECAP Management Co. 3 857 960 4,16%
Temasek Holdings Pte Ltd. (Investment Management) 2 748 056 2,96%
Invesco Advisers, Inc. 2 317 439 2,50%
Capital Research & Management Co. (Global Investors) 1 828 239 1,97%
Capital Research & Management Co. (World Investors) 1 828 239 1,97%
Belangnemingen
NaamAandelen%Totale waarde
LEAP THERAPEUTICS, INC. (LPTX) 4 804 637 8,05% 8 263 976 USD
Bedrijfsgegevens
BeiGene Ltd.
Zhongguancun Life Science Park
No. 30 Science Park Road
Changping District
Beijing 102206

Phone : +86.10.58958000
Fax : +86.10.58958080
Web : http://www.beigene.com
Merk portefeuille
In samenwerking metMijn merken op de beurs
Meer merken vanBeiGene, Ltd.
Sector Biotherapeutische geneesmiddelen
Verschil t.o.v. 1 jan (%)Kapitalisatie (M$)
BEIGENE, LTD.56.02%37 507
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850
GENMAB A/S9.62%27 860
ARGENX SE15.74%16 900
CUREVAC N.V.-32.02%10 301
ASCENDIS PHARMA A/S-3.16%9 180
NEUROCRINE BIOSCIENCES, INC.0.68%9 133
MIRATI THERAPEUTICS, INC.-20.76%8 985
ACCELERON PHARMA INC.7.55%8 380
HUALAN BIOLOGICAL ENGINEERING INC.-33.17%7 965
GW PHARMACEUTICALS PLC89.72%6 907
SAREPTA THERAPEUTICS, INC.-49.33%6 897
FATE THERAPEUTICS, INC.-21.26%6 815
ARROWHEAD PHARMACEUTICALS, INC.-15.38%6 770
ULTRAGENYX PHARMACEUTICAL INC.-29.01%6 666
EXELIXIS, INC.3.24%6 528
REMEGEN CO., LTD.8.11%6 465